Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Cancer Biologics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Cancer Biologics Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Cancer Biologics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Monoclonal Antibodies
    • 1.4.3 Vaccines
    • 1.4.4 Cell and Gene Therapy
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Cancer Biologics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Cancer Biologics Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Cancer Biologics Industry
      • 1.6.1.1 Cancer Biologics Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Cancer Biologics Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Cancer Biologics Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Cancer Biologics Market Perspective (2015-2026)
  • 2.2 Cancer Biologics Growth Trends by Regions
    • 2.2.1 Cancer Biologics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Cancer Biologics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Cancer Biologics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Cancer Biologics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Cancer Biologics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Cancer Biologics Players by Market Size
    • 3.1.1 Global Top Cancer Biologics Players by Revenue (2015-2020)
    • 3.1.2 Global Cancer Biologics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Cancer Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Cancer Biologics Market Concentration Ratio
    • 3.2.1 Global Cancer Biologics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Cancer Biologics Revenue in 2019
  • 3.3 Cancer Biologics Key Players Head office and Area Served
  • 3.4 Key Players Cancer Biologics Product Solution and Service
  • 3.5 Date of Enter into Cancer Biologics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Cancer Biologics Historic Market Size by Type (2015-2020)
  • 4.2 Global Cancer Biologics Forecasted Market Size by Type (2021-2026)

5 Cancer Biologics Breakdown Data by Application (2015-2026)

  • 5.1 Global Cancer Biologics Market Size by Application (2015-2020)
  • 5.2 Global Cancer Biologics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Cancer Biologics Market Size (2015-2020)
  • 6.2 Cancer Biologics Key Players in North America (2019-2020)
  • 6.3 North America Cancer Biologics Market Size by Type (2015-2020)
  • 6.4 North America Cancer Biologics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Cancer Biologics Market Size (2015-2020)
  • 7.2 Cancer Biologics Key Players in Europe (2019-2020)
  • 7.3 Europe Cancer Biologics Market Size by Type (2015-2020)
  • 7.4 Europe Cancer Biologics Market Size by Application (2015-2020)

8 China

  • 8.1 China Cancer Biologics Market Size (2015-2020)
  • 8.2 Cancer Biologics Key Players in China (2019-2020)
  • 8.3 China Cancer Biologics Market Size by Type (2015-2020)
  • 8.4 China Cancer Biologics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Cancer Biologics Market Size (2015-2020)
  • 9.2 Cancer Biologics Key Players in Japan (2019-2020)
  • 9.3 Japan Cancer Biologics Market Size by Type (2015-2020)
  • 9.4 Japan Cancer Biologics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Cancer Biologics Market Size (2015-2020)
  • 10.2 Cancer Biologics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Cancer Biologics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Cancer Biologics Market Size by Application (2015-2020)

11 India

  • 11.1 India Cancer Biologics Market Size (2015-2020)
  • 11.2 Cancer Biologics Key Players in India (2019-2020)
  • 11.3 India Cancer Biologics Market Size by Type (2015-2020)
  • 11.4 India Cancer Biologics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Cancer Biologics Market Size (2015-2020)
  • 12.2 Cancer Biologics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Cancer Biologics Market Size by Type (2015-2020)
  • 12.4 Central & South America Cancer Biologics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Roche
    • 13.1.1 Roche Company Details
    • 13.1.2 Roche Business Overview and Its Total Revenue
    • 13.1.3 Roche Cancer Biologics Introduction
    • 13.1.4 Roche Revenue in Cancer Biologics Business (2015-2020))
    • 13.1.5 Roche Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview and Its Total Revenue
    • 13.2.3 Novartis Cancer Biologics Introduction
    • 13.2.4 Novartis Revenue in Cancer Biologics Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 Eli Lilly
    • 13.3.1 Eli Lilly Company Details
    • 13.3.2 Eli Lilly Business Overview and Its Total Revenue
    • 13.3.3 Eli Lilly Cancer Biologics Introduction
    • 13.3.4 Eli Lilly Revenue in Cancer Biologics Business (2015-2020)
    • 13.3.5 Eli Lilly Recent Development
  • 13.4 Sanofi
    • 13.4.1 Sanofi Company Details
    • 13.4.2 Sanofi Business Overview and Its Total Revenue
    • 13.4.3 Sanofi Cancer Biologics Introduction
    • 13.4.4 Sanofi Revenue in Cancer Biologics Business (2015-2020)
    • 13.4.5 Sanofi Recent Development
  • 13.5 Celgene
    • 13.5.1 Celgene Company Details
    • 13.5.2 Celgene Business Overview and Its Total Revenue
    • 13.5.3 Celgene Cancer Biologics Introduction
    • 13.5.4 Celgene Revenue in Cancer Biologics Business (2015-2020)
    • 13.5.5 Celgene Recent Development
  • 13.6 Pfizer
    • 13.6.1 Pfizer Company Details
    • 13.6.2 Pfizer Business Overview and Its Total Revenue
    • 13.6.3 Pfizer Cancer Biologics Introduction
    • 13.6.4 Pfizer Revenue in Cancer Biologics Business (2015-2020)
    • 13.6.5 Pfizer Recent Development
  • 13.7 Bayer
    • 13.7.1 Bayer Company Details
    • 13.7.2 Bayer Business Overview and Its Total Revenue
    • 13.7.3 Bayer Cancer Biologics Introduction
    • 13.7.4 Bayer Revenue in Cancer Biologics Business (2015-2020)
    • 13.7.5 Bayer Recent Development
  • 13.8 Johnson & Johnson
    • 13.8.1 Johnson & Johnson Company Details
    • 13.8.2 Johnson & Johnson Business Overview and Its Total Revenue
    • 13.8.3 Johnson & Johnson Cancer Biologics Introduction
    • 13.8.4 Johnson & Johnson Revenue in Cancer Biologics Business (2015-2020)
    • 13.8.5 Johnson & Johnson Recent Development
  • 13.9 Bristol-Myers Squibb
    • 13.9.1 Bristol-Myers Squibb Company Details
    • 13.9.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
    • 13.9.3 Bristol-Myers Squibb Cancer Biologics Introduction
    • 13.9.4 Bristol-Myers Squibb Revenue in Cancer Biologics Business (2015-2020)
    • 13.9.5 Bristol-Myers Squibb Recent Development
  • 13.10 Merck
    • 13.10.1 Merck Company Details
    • 13.10.2 Merck Business Overview and Its Total Revenue
    • 13.10.3 Merck Cancer Biologics Introduction
    • 13.10.4 Merck Revenue in Cancer Biologics Business (2015-2020)
    • 13.10.5 Merck Recent Development
  • 13.11 Amgen
    • 10.11.1 Amgen Company Details
    • 10.11.2 Amgen Business Overview and Its Total Revenue
    • 10.11.3 Amgen Cancer Biologics Introduction
    • 10.11.4 Amgen Revenue in Cancer Biologics Business (2015-2020)
    • 10.11.5 Amgen Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Cancer Biologics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Biologics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Roche
    Novartis
    Eli Lilly
    Sanofi
    Celgene
    Pfizer
    Bayer
    Johnson & Johnson
    Bristol-Myers Squibb
    Merck
    Amgen

    Market segment by Type, the product can be split into
    Monoclonal Antibodies
    Vaccines
    Cell and Gene Therapy
    Others
    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Cancer Biologics status, future forecast, growth opportunity, key market and key players.
    To present the Cancer Biologics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Cancer Biologics are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now